Blood levels of a specific form of phosphorylated tau effectively identify Alzheimer disease (AD), two new studies have shown. The findings could lead to a highly accurate diagnostic blood test with the potential to predict AD up to 20 years before disease onset.
AD is defined by amyloid-β (Aβ) and tau pathology in the brain, but pathological confirmation of AD in living people is difficult. Aβ-PET can reveal brain Aβ deposition but is costly and rarely used in clinical practice. Similarly, cerebrospinal fluid (CSF) levels of Aβ, tau and neurofilament light (NfL) are…
